Clinical Trials Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Study Design (Interventional Trials and Expanded Access Trials), Indications (Autoimmune Diseases/Inflammation, Pain Management, Oncological Conditions, Neurological Disorders, Diabetes, Obesity, Metabolic Disorders, Cardiovascular Diseases, and Others), Phase Type (Phase I, Phase II, and Phase III), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
The clinical trials market is anticipated to grow from US$ 43.37 billion in 2023 and is projected to reach US$ 73.33 billion by 2031; it is expected to register a CAGR of 6.8% during 2023–2031. The... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe clinical trials market is anticipated to grow from US$ 43.37 billion in 2023 and is projected to reach US$ 73.33 billion by 2031; it is expected to register a CAGR of 6.8% during 2023–2031. The practice of outsourcing clinical studies with a massive rise in the number of trials and the flourishing pharmaceutical industry with a surge in R&D activities are contributing to the clinical trials market growth. However, the expensive and time-consuming nature of trials hampers market growth. Further, AI-driven clinical trials are expected to bring new clinical trials market trends in the coming years.Clinical trials are research studies that test a medical, surgical, or behavioral intervention in people. These trials are the primary way that researchers determine if a new form of treatment or prevention, such as a new drug, diet, or medical device (for example, a pacemaker), is safe and effective in people. Often, a clinical trial is designed to learn if a new treatment is more effective or has less harmful side effects than existing treatments. North America accounted for a major share of the global clinical trials market in 2023. The clinical trials market in North America is segmented into the US, Canada, and Mexico. The US has become a leading clinical research destination. Nearly half of the clinical trials are conducted in the US. Additionally, most pharmaceutical research companies prefer to conduct clinical trials in the US due to established medical infrastructure, rapid approval timelines, a favorable regulatory framework, and accepted clinical trial-generated data globally. A World Health Organization (WHO) report states that the US had the highest number of clinical trials, with 157,618 trials in 2021. The growth of the clinical trials market in the US can be attributed to innovative products launched by companies for applications in clinical trials. Medical Metrics, a clinical research organization (CRO) providing various services for clinical trials, offers "Assessa." This product assists in the decision-making process of drug discovery and related clinical studies. It helps discover drugs for neurological disorders, such as dementia, cognitive impairment, Alzheimer's disease, Parkinson's Disease, Schizophrenia, and other memory-related diseases. The rising number of clinical trials in the US favors the growth of the clinical trials market in the country. Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials to Provide Market Opportunities in Future Subjects enrolled in decentralized clinical trials (DCT) do not need to access hospital-based trial sites frequently. In DCTs, digital technologies are used to enable access of patients for clinical research, remote data collection and monitoring, and communication between investigators and participants. A hybrid clinical trial approach combines home-based and on-site activities, bringing the best patient experience and meeting complex protocol regimes, gaining traction across various therapeutic areas and trial phase journeys. Initially, the adoption of DCT was affected due to challenges such as patient privacy, data security, regulatory barriers, and complex protocol regimes. However, the COVID-19 pandemic compelled the sponsors of clinical trials to adopt decentralized and hybrid clinical techniques for developing drugs, as in-person studies were not feasible amid this health crisis. With restrictions imposed on commute, the only way to gather data and keep trials going was to work remotely and make optimal use of technologies to accelerate processes. According to the data provided by McKinsey, ~70% of the potential participants for clinical trials stay away from trial sites. Therefore, decentralization broadens trial access to reach a larger number of subjects, consisting of potentially a more diverse pool of patients. Hybrid clinical trials allow sponsors to strategically incorporate DCT elements into study designs. These trial models offer unprecedented flexibility; thus, more companies are showing interest in hybrid trials, which is redefining the industry landscape. According to ObvioHealth, the FDA had plans to unveil protocols to support the use of DCT methods in 2023 to enhance the credibility of future clinical research. Thus, the increasing focus on using decentralized and hybrid clinical trials over traditional clinical trial methods is expected to provide lucrative opportunities for the clinical trials market during the forecast period. Study Design -Based Insights Based on study design, the market is bifurcated into interventional trials and expanded access trials. Indication -Based Insights By indication, the market is segmented into cardiovascular diseases, oncological conditions, neurological disorders, autoimmune diseases/inflammation, pain management, diabetes, obesity, metabolic disorders, and others. Phase -Based Insights Based on phase, the clinical trials market is divided into Phase I, Phase II, and Phase III. Clinical Trials Market: Competitive Landscape and Key Developments IQVIA Holdings Inc, Parexel International Corporation, IXICO Plc, Charles River Laboratories Inc, ICON Plc, WuXi AppTec Co Ltd, SGS SA, Syneos Health Inc, SIRO Clinpharm Private Limited, Thermo Fisher Scientific Inc, Laboratory Corp of America Holdings, CliniRx, Caidya, Oracle Corp, and Medpace are among the key companies operating in the clinical trials market. The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are among the primary and secondary sources referred to while preparing the clinical trials market report. Table of ContentsTABLE OF CONTENTS1. Introduction 1.1 The Insight Partners Research Report Guidance 1.2 Market Segmentation 2. Executive Summary 2.1 Key Insights 3. Research Methodology 3.1 Secondary Research 3.2 Primary Research 3.2.1 Hypothesis formulation: 3.2.2 Macro-economic factor analysis: 3.2.3 Developing base number: 3.2.4 Data Triangulation: 3.2.5 Country level data: 4. Clinical Trials Market Landscape 4.1 Overview 4.2 PEST Analysis 5. Clinical Trials Market – Key Market Dynamics 5.1 Clinical Trials Market – Key Market Dynamics 5.2 Market Drivers 5.2.1 Practice of Outsourcing Clinical Studies with Massive Rise in Number of Trials 5.2.2 Flourishing Pharmaceutical Industry with Surge in R&D Activities 5.3 Market Restraints 5.3.1 Expensive and Time-Consuming Process 5.4 Market Opportunities 5.4.1 Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials 5.5 Future Trends 5.5.1 AI-Driven Clinical Trials 5.6 Impact of Drivers and Restraints: 6. Clinical Trials Market – Global Market Analysis 6.1 Clinical Trials Market Revenue (US$ Million), 2021–2031 6.2 Global Clinical Trials Market Forecast Analysis 7. Clinical Trials Market Analysis – by Study Design 7.1 Interventional Trials 7.1.1 Overview 7.1.2 Interventional Trials: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 7.2 Expanded Access Trials 7.2.1 Overview 7.2.2 Expanded Access Trials: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 8. Clinical Trials Market Analysis – by Indications 8.1 Autoimmune Diseases/Inflammation 8.1.1 Overview 8.1.2 Autoimmune Diseases/Inflammation : Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 8.2 Pain Management 8.2.1 Overview 8.2.2 Pain Management: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 8.3 Oncological Conditions 8.3.1 Overview 8.3.2 Oncological Conditions: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 8.4 Neurological Disorders 8.4.1 Overview 8.4.2 Neurological Disorders: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 8.5 Diabetes 8.5.1 Overview 8.5.2 Diabetes: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 8.6 Obesity 8.6.1 Overview 8.6.2 Obesity: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 8.7 Metabolic Disorders 8.7.1 Overview 8.7.2 Metabolic Disorders: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 8.8 Cardiovascular Diseases 8.8.1 Overview 8.8.2 Cardiovascular Diseases: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 8.9 Others 8.9.1 Overview 8.9.2 Others: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 9. Clinical Trials Market Analysis – by Phase 9.1 Phase I 9.1.1 Overview 9.1.2 Phase I: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 9.2 Phase II 9.2.1 Overview 9.2.2 Phase II: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 9.3 Phase III 9.3.1 Overview 9.3.2 Phase III: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10. Clinical Trials Market – Geographical Analysis 10.1 Overview 10.2 North America 10.2.1 North America Clinical Trials Market Overview 10.2.2 North America: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.2.2.1 North America: Clinical Trials Market – Revenue and Forecast Analysis – by Study Design 10.2.2.2 North America: Clinical Trials Market – Revenue and Forecast Analysis – by Indications 10.2.2.3 North America: Clinical Trials Market – Revenue and Forecast Analysis – by Phase 10.2.3 North America: Clinical Trials Market – Revenue and Forecast Analysis – by Country 10.2.3.1 United States: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.2.3.1.1 United States: Clinical Trials Market Breakdown, by Study Design 10.2.3.1.2 United States: Clinical Trials Market Breakdown, by Indications 10.2.3.1.3 United States: Clinical Trials Market Breakdown, by Phase 10.2.3.2 Canada: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.2.3.2.1 Canada: Clinical Trials Market Breakdown, by Study Design 10.2.3.2.2 Canada: Clinical Trials Market Breakdown, by Indications 10.2.3.2.3 Canada: Clinical Trials Market Breakdown, by Phase 10.2.3.3 Mexico: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.2.3.3.1 Mexico: Clinical Trials Market Breakdown, by Study Design 10.2.3.3.2 Mexico: Clinical Trials Market Breakdown, by Indications 10.2.3.3.3 Mexico: Clinical Trials Market Breakdown, by Phase 10.3 Europe 10.3.1 Europe Clinical Trials Market Overview 10.3.2 Europe: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.3.2.1 Europe: Clinical Trials Market – Revenue and Forecast Analysis – by Study Design 10.3.2.2 Europe: Clinical Trials Market – Revenue and Forecast Analysis – by Indications 10.3.2.3 Europe: Clinical Trials Market – Revenue and Forecast Analysis – by Phase 10.3.3 Europe: Clinical Trials Market – Revenue and Forecast Analysis – by Country 10.3.3.1 United Kingdom: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.3.3.1.1 United Kingdom: Clinical Trials Market Breakdown, by Study Design 10.3.3.1.2 United Kingdom: Clinical Trials Market Breakdown, by Indications 10.3.3.1.3 United Kingdom: Clinical Trials Market Breakdown, by Phase 10.3.3.2 Germany: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.3.3.2.1 Germany: Clinical Trials Market Breakdown, by Study Design 10.3.3.2.2 Germany: Clinical Trials Market Breakdown, by Indications 10.3.3.2.3 Germany: Clinical Trials Market Breakdown, by Phase 10.3.3.3 France: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.3.3.3.1 France: Clinical Trials Market Breakdown, by Study Design 10.3.3.3.2 France: Clinical Trials Market Breakdown, by Indications 10.3.3.3.3 France: Clinical Trials Market Breakdown, by Phase 10.3.3.4 Spain: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.3.3.4.1 Spain: Clinical Trials Market Breakdown, by Study Design 10.3.3.4.2 Spain: Clinical Trials Market Breakdown, by Indications 10.3.3.4.3 Spain: Clinical Trials Market Breakdown, by Phase 10.3.3.5 Italy: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.3.3.5.1 Italy: Clinical Trials Market Breakdown, by Study Design 10.3.3.5.2 Italy: Clinical Trials Market Breakdown, by Indications 10.3.3.5.3 Italy: Clinical Trials Market Breakdown, by Phase 10.3.3.6 Poland: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.3.3.6.1 Poland: Clinical Trials Market Breakdown, by Study Design 10.3.3.6.2 Poland: Clinical Trials Market Breakdown, by Indications 10.3.3.6.3 Poland: Clinical Trials Market Breakdown, by Phase 10.3.3.7 Switzerland: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.3.3.7.1 Switzerland: Clinical Trials Market Breakdown, by Study Design 10.3.3.7.2 Switzerland: Clinical Trials Market Breakdown, by Indications 10.3.3.7.3 Switzerland: Clinical Trials Market Breakdown, by Phase 10.3.3.8 Sweden: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.3.3.8.1 Sweden: Clinical Trials Market Breakdown, by Study Design 10.3.3.8.2 Sweden: Clinical Trials Market Breakdown, by Indications 10.3.3.8.3 Sweden: Clinical Trials Market Breakdown, by Phase 10.3.3.9 Denmark: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.3.3.9.1 Denmark: Clinical Trials Market Breakdown, by Study Design 10.3.3.9.2 Denmark: Clinical Trials Market Breakdown, by Indications 10.3.3.9.3 Denmark: Clinical Trials Market Breakdown, by Phase 10.3.3.10 Belgium: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.3.3.10.1 Belgium: Clinical Trials Market Breakdown, by Study Design 10.3.3.10.2 Belgium: Clinical Trials Market Breakdown, by Indications 10.3.3.10.3 Belgium: Clinical Trials Market Breakdown, by Phase 10.3.3.11 Netherlands: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.3.3.11.1 Netherlands: Clinical Trials Market Breakdown, by Study Design 10.3.3.11.2 Netherlands: Clinical Trials Market Breakdown, by Indications 10.3.3.11.3 Netherlands: Clinical Trials Market Breakdown, by Phase 10.3.3.12 Rest of Europe: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.3.3.12.1 Rest of Europe: Clinical Trials Market Breakdown, by Study Design 10.3.3.12.2 Rest of Europe: Clinical Trials Market Breakdown, by Indications 10.3.3.12.3 Rest of Europe: Clinical Trials Market Breakdown, by Phase 10.4 Asia Pacific 10.4.1 Asia Pacific Clinical Trials Market Overview 10.4.2 Asia Pacific: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.4.2.1 Asia Pacific: Clinical Trials Market – Revenue and Forecast Analysis – by Study Design 10.4.2.2 Asia Pacific: Clinical Trials Market – Revenue and Forecast Analysis – by Indications 10.4.2.3 Asia Pacific: Clinical Trials Market – Revenue and Forecast Analysis – by Phase 10.4.3 Asia Pacific: Clinical Trials Market – Revenue and Forecast Analysis – by Country 10.4.3.1 China: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.4.3.1.1 China: Clinical Trials Market Breakdown, by Study Design 10.4.3.1.2 China: Clinical Trials Market Breakdown, by Indications 10.4.3.1.3 China: Clinical Trials Market Breakdown, by Phase 10.4.3.2 Japan: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.4.3.2.1 Japan: Clinical Trials Market Breakdown, by Study Design 10.4.3.2.2 Japan: Clinical Trials Market Breakdown, by Indications 10.4.3.2.3 Japan: Clinical Trials Market Breakdown, by Phase 10.4.3.3 India: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.4.3.3.1 India: Clinical Trials Market Breakdown, by Study Design 10.4.3.3.2 India: Clinical Trials Market Breakdown, by Indications 10.4.3.3.3 India: Clinical Trials Market Breakdown, by Phase 10.4.3.4 Australia: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.4.3.4.1 Australia: Clinical Trials Market Breakdown, by Study Design 10.4.3.4.2 Australia: Clinical Trials Market Breakdown, by Indications 10.4.3.4.3 Australia: Clinical Trials Market Breakdown, by Phase 10.4.3.5 South Korea: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.4.3.5.1 South Korea: Clinical Trials Market Breakdown, by Study Design 10.4.3.5.2 South Korea: Clinical Trials Market Breakdown, by Indications 10.4.3.5.3 South Korea: Clinical Trials Market Breakdown, by Phase 10.4.3.6 Indonesia: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.4.3.6.1 Indonesia: Clinical Trials Market Breakdown, by Study Design 10.4.3.6.2 Indonesia: Clinical Trials Market Breakdown, by Indications 10.4.3.6.3 Indonesia: Clinical Trials Market Breakdown, by Phase 10.4.3.7 Malaysia: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.4.3.7.1 Malaysia: Clinical Trials Market Breakdown, by Study Design 10.4.3.7.2 Malaysia: Clinical Trials Market Breakdown, by Indications 10.4.3.7.3 Malaysia: Clinical Trials Market Breakdown, by Phase 10.4.3.8 Singapore: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.4.3.8.1 Singapore: Clinical Trials Market Breakdown, by Study Design 10.4.3.8.2 Singapore: Clinical Trials Market Breakdown, by Indications 10.4.3.8.3 Singapore: Clinical Trials Market Breakdown, by Phase 10.4.3.9 Rest of APAC: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.4.3.9.1 Rest of APAC: Clinical Trials Market Breakdown, by Study Design 10.4.3.9.2 Rest of APAC: Clinical Trials Market Breakdown, by Indications 10.4.3.9.3 Rest of APAC: Clinical Trials Market Breakdown, by Phase 10.5 Middle East and Africa 10.5.1 Middle East and Africa Clinical Trials Market Overview 10.5.2 Middle East and Africa: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.5.2.1 Middle East and Africa: Clinical Trials Market – Revenue and Forecast Analysis – by Study Design 10.5.2.2 Middle East and Africa: Clinical Trials Market – Revenue and Forecast Analysis – by Indications 10.5.2.3 Middle East and Africa: Clinical Trials Market – Revenue and Forecast Analysis – by Phase 10.5.3 Middle East and Africa: Clinical Trials Market – Revenue and Forecast Analysis – by Country 10.5.3.1 Saudi Arabia: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.5.3.1.1 Saudi Arabia: Clinical Trials Market Breakdown, by Study Design 10.5.3.1.2 Saudi Arabia: Clinical Trials Market Breakdown, by Indications 10.5.3.1.3 Saudi Arabia: Clinical Trials Market Breakdown, by Phase 10.5.3.2 South Africa: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.5.3.2.1 South Africa: Clinical Trials Market Breakdown, by Study Design 10.5.3.2.2 South Africa: Clinical Trials Market Breakdown, by Indications 10.5.3.2.3 South Africa: Clinical Trials Market Breakdown, by Phase 10.5.3.3 United Arab Emirates: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.5.3.3.1 United Arab Emirates: Clinical Trials Market Breakdown, by Study Design 10.5.3.3.2 United Arab Emirates: Clinical Trials Market Breakdown, by Indications 10.5.3.3.3 United Arab Emirates: Clinical Trials Market Breakdown, by Phase 10.5.3.4 Rest of Middle East and Africa: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.5.3.4.1 Rest of Middle East and Africa: Clinical Trials Market Breakdown, by Study Design 10.5.3.4.2 Rest of Middle East and Africa: Clinical Trials Market Breakdown, by Indications 10.5.3.4.3 Rest of Middle East and Africa: Clinical Trials Market Breakdown, by Phase 10.6 South and Central America 10.6.1 South and Central America Clinical Trials Market Overview 10.6.2 South and Central America: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.6.2.1 South and Central America: Clinical Trials Market – Revenue and Forecast Analysis – by Study Design 10.6.2.2 South and Central America: Clinical Trials Market – Revenue and Forecast Analysis – by Indications 10.6.2.3 South and Central America: Clinical Trials Market – Revenue and Forecast Analysis – by Phase 10.6.3 South and Central America: Clinical Trials Market – Revenue and Forecast Analysis – by Country 10.6.3.1 Brazil: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.6.3.1.1 Brazil: Clinical Trials Market Breakdown, by Study Design 10.6.3.1.2 Brazil: Clinical Trials Market Breakdown, by Indications 10.6.3.1.3 Brazil: Clinical Trials Market Breakdown, by Phase 10.6.3.2 Argentina: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.6.3.2.1 Argentina: Clinical Trials Market Breakdown, by Study Design 10.6.3.2.2 Argentina: Clinical Trials Market Breakdown, by Indications 10.6.3.2.3 Argentina: Clinical Trials Market Breakdown, by Phase 10.6.3.3 Rest of South and Central America: Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million) 10.6.3.3.1 Rest of South and Central America: Clinical Trials Market Breakdown, by Study Design 10.6.3.3.2 Rest of South and Central America: Clinical Trials Market Breakdown, by Indications 10.6.3.3.3 Rest of South and Central America: Clinical Trials Market Breakdown, by Phase 11. Industry Landscape 11.1 Overview 11.2 Growth Strategies in Clinical Trials Market 11.3 Organic Growth Strategies 11.3.1 Overview 11.4 Inorganic Growth Strategies 11.4.1 Overview 12. Company Profiles 12.1 QVIA Holdings Inc 12.1.1 Key Facts 12.1.2 Business Description 12.1.3 Products and Services 12.1.4 Financial Overview 12.1.5 SWOT Analysis 12.1.6 Key Developments 12.2 Parexel International Corp 12.2.1 Key Facts 12.2.2 Business Description 12.2.3 Products and Services 12.2.4 Financial Overview 12.2.5 SWOT Analysis 12.2.6 Key Developments 12.3 IXICO Plc 12.3.1 Key Facts 12.3.2 Business Description 12.3.3 Products and Services 12.3.4 Financial Overview 12.3.5 SWOT Analysis 12.3.6 Key Developments 12.4 Charles River Laboratories International Inc 12.4.1 Key Facts 12.4.2 Business Description 12.4.3 Products and Services 12.4.4 Financial Overview 12.4.5 SWOT Analysis 12.4.6 Key Developments 12.5 ICON Plc 12.5.1 Key Facts 12.5.2 Business Description 12.5.3 Products and Services 12.5.4 Financial Overview 12.5.5 SWOT Analysis 12.5.6 Key Developments 12.6 WuXi AppTec Co Ltd 12.6.1 Key Facts 12.6.2 Business Description 12.6.3 Products and Services 12.6.4 Financial Overview 12.6.5 SWOT Analysis 12.6.6 Key Developments 12.7 SGS SA 12.7.1 Key Facts 12.7.2 Business Description 12.7.3 Products and Services 12.7.4 Financial Overview 12.7.5 SWOT Analysis 12.7.6 Key Developments 12.8 Syneos Health Inc 12.8.1 Key Facts 12.8.2 Business Description 12.8.3 Products and Services 12.8.4 Financial Overview 12.8.5 SWOT Analysis 12.8.6 Key Developments 12.9 SIRO Clinpharm Pvt Ltd 12.9.1 Key Facts 12.9.2 Business Description 12.9.3 Products and Services 12.9.4 Financial Overview 12.9.5 SWOT Analysis 12.9.6 Key Developments 12.10 Thermo Fisher Scientific Inc 12.10.1 Key Facts 12.10.2 Business Description 12.10.3 Products and Services 12.10.4 Financial Overview 12.10.5 SWOT Analysis 12.10.6 Key Developments 12.11 Laboratory Corp of America Holdings 12.11.1 Key Facts 12.11.2 Business Description 12.11.3 Products and Services 12.11.4 Financial Overview 12.11.5 SWOT Analysis 12.11.6 Key Developments 12.12 CliniRx Research Private Limited 12.12.1 Key Facts 12.12.2 Business Description 12.12.3 Products and Services 12.12.4 Financial Overview 12.12.5 SWOT Analysis 12.12.6 Key Developments 12.13 Caidya 12.13.1 Key Facts 12.13.2 Business Description 12.13.3 Products and Services 12.13.4 Financial Overview 12.13.5 SWOT Analysis 12.13.6 Key Developments 12.14 Oracle Corp 12.14.1 Key Facts 12.14.2 Business Description 12.14.3 Products and Services 12.14.4 Financial Overview 12.14.5 SWOT Analysis 12.14.6 Key Developments 12.15 Medpace Holdings Inc 12.15.1 Key Facts 12.15.2 Business Description 12.15.3 Products and Services 12.15.4 Financial Overview 12.15.5 SWOT Analysis 12.15.6 Key Developments 13. Appendix 13.1 About The Insight Partners 13.2 Glossary of Terms
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(個々の器官作用薬)の最新刊レポート
The Insight Partners 社の最新刊レポート
本レポートと同じKEY WORD(asia pacific)の最新刊レポート
よくあるご質問The Insight Partners社はどのような調査会社ですか?The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/25 10:26 153.16 円 166.17 円 201.34 円 |